Hey SP, Franklin JM, Avorn J, Kesselheim AS (2017). Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors Circulation: Cardiovascular Quality and Outcomes 10(6):e003121.
Hey SP (2017). Clinical trial participants should have a say in new drug pricing. STAT News, May 18.
Hey SP & Barsanti-Innes B (2017). Epistemology, Ethics, and Progress in Precision Medicine. Perspectives in Biology and Medicine 59(3):293-310.
Hey SP & Kesselheim AS (2017). Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations. Hastings Center Report 47(2):16-20.
I received my Ph.D. in philosophy from the University of Western Ontario and my B.A. in philosophy from the University of Illinois at Chicago. I previously held a research fellowship in the Biomedical Ethics Unit at McGill University and a visiting scholarship in the Ethox Centre at the University of Oxford.
In 2015, I joined the faculty at the Harvard Center for Bioethics and was appointed as a research fellow in the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology & Pharmacoeconomics at the Brigham and Women’s Hospital in Boston, Massachusetts.
You can now also follow me on twitter!